Topic: Affordable Care Act

JD Supra Corporate Brief: Workplace Harassment, Vicarious Liability, Resource Nationalism, Wild Kingdom

To go with today’s JD Supra Corporate Brief, we’d recommend a nice, full-bodied 2013 Arabica-Robusta blend from Brazil… How are companies responding to workplace harassment, discrimination and retaliation? Read this benchmark survey… (NAVEX Global) The European Union is on the cusp of implementing new rules that will require greater transparency on payments made in the… Read more »

FTC Issues Favorable Opinion for Clinical Integration Program

In its first advisory opinion letter issued since implementation began on the Affordable Care Act, the Federal Trade Commission indicated that it would not challenge a proposal from the Norman Physician Hospital Organization (PHO) to form a clinical integration program (CIP). For your reference, a roundup of legal commentary and analysis on the FTC opinion.… Read more »

[Video] Corporate Law Report: News to Use Now

Welcome to 2013′s inaugural edition of the Corporate Law Report, a look at some of the top corporate news items we’ve been following this first week of the new year. You know the drill: Watch the video overview above and, for any topics that interest you, go deeper with the legal analysis and commentary below>>… Read more »

IRS Defines “Full-Time” Employees for Health Care Benefits

Earlier this month, the Internal Revenue Service issued important guidance for employers on the rules for identifying “full-time” employees for the purposes of the Affordable Care Act. It’s an important clarification, write employment attorneys Josh Bobrin and Edward Leeds (Ballard Spahr), because: “Effective January 1, 2014, employers with 50 or more full-time equivalent employees are… Read more »

Biosimilars Benefit From Health Care Reform Decision

“With [the] Supreme Court affirmance of the bulk of the Affordable Care Act, the specter that the BPCIA framework for biosimilar introduction could be dismantled is no longer a concern. Presumably it will be full speed ahead through the regulatory process, and we will see biosimilar applications for approval and attendant patent litigation before too… Read more »